Cargando…
Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor
Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone mainly produced by bone that acts in the kidney through FGF receptors and Klotho. Here we investigated whether the kidney was an additional source of FGF23 during renal disease using a model of type 2 diabetic nephropathy. Renal expressio...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743899/ https://www.ncbi.nlm.nih.gov/pubmed/23967103 http://dx.doi.org/10.1371/journal.pone.0070775 |
_version_ | 1782280539845165056 |
---|---|
author | Zanchi, Cristina Locatelli, Monica Benigni, Ariela Corna, Daniela Tomasoni, Susanna Rottoli, Daniela Gaspari, Flavio Remuzzi, Giuseppe Zoja, Carlamaria |
author_facet | Zanchi, Cristina Locatelli, Monica Benigni, Ariela Corna, Daniela Tomasoni, Susanna Rottoli, Daniela Gaspari, Flavio Remuzzi, Giuseppe Zoja, Carlamaria |
author_sort | Zanchi, Cristina |
collection | PubMed |
description | Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone mainly produced by bone that acts in the kidney through FGF receptors and Klotho. Here we investigated whether the kidney was an additional source of FGF23 during renal disease using a model of type 2 diabetic nephropathy. Renal expression of FGF23 and Klotho was assessed in Zucker diabetic fatty (ZDF) and control lean rats at 2, 4, 6, 8 months of age. To evaluate whether the renoprotective effect of angiotensin converting enzyme (ACE) inhibitor in this model was associated with changes in FGF23 and Klotho, ZDF rats received ramipril from 4, when proteinuric, to 8 months of age. FGF23 mRNA was not detectable in the kidney of lean rats, nor of ZDF rats at 2 months of age. FGF23 became measurable in the kidney of diabetic rats at 4 months and significantly increased thereafter. FGF23 protein localized in proximal and distal tubules. Renal Klotho mRNA and protein decreased during time in ZDF rats. As renal disease progressed, serum phosphate levels increased in parallel with decline of fractional phosphorus excretion. Ramipril limited proteinuria and renal injury, attenuated renal FGF23 upregulation and ameliorated Klotho expression. Ramipril normalized serum phosphate levels and tended to increase fractional phosphorus excretion. These data indicate that during progressive renal disease the kidney is a site of FGF23 production which is limited by ACE inhibition. Interfering pharmacologically with the delicate balance of FGF23 and phosphorus in diabetes may have implications in clinics. |
format | Online Article Text |
id | pubmed-3743899 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-37438992013-08-21 Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor Zanchi, Cristina Locatelli, Monica Benigni, Ariela Corna, Daniela Tomasoni, Susanna Rottoli, Daniela Gaspari, Flavio Remuzzi, Giuseppe Zoja, Carlamaria PLoS One Research Article Fibroblast growth factor 23 (FGF23) is a phosphaturic hormone mainly produced by bone that acts in the kidney through FGF receptors and Klotho. Here we investigated whether the kidney was an additional source of FGF23 during renal disease using a model of type 2 diabetic nephropathy. Renal expression of FGF23 and Klotho was assessed in Zucker diabetic fatty (ZDF) and control lean rats at 2, 4, 6, 8 months of age. To evaluate whether the renoprotective effect of angiotensin converting enzyme (ACE) inhibitor in this model was associated with changes in FGF23 and Klotho, ZDF rats received ramipril from 4, when proteinuric, to 8 months of age. FGF23 mRNA was not detectable in the kidney of lean rats, nor of ZDF rats at 2 months of age. FGF23 became measurable in the kidney of diabetic rats at 4 months and significantly increased thereafter. FGF23 protein localized in proximal and distal tubules. Renal Klotho mRNA and protein decreased during time in ZDF rats. As renal disease progressed, serum phosphate levels increased in parallel with decline of fractional phosphorus excretion. Ramipril limited proteinuria and renal injury, attenuated renal FGF23 upregulation and ameliorated Klotho expression. Ramipril normalized serum phosphate levels and tended to increase fractional phosphorus excretion. These data indicate that during progressive renal disease the kidney is a site of FGF23 production which is limited by ACE inhibition. Interfering pharmacologically with the delicate balance of FGF23 and phosphorus in diabetes may have implications in clinics. Public Library of Science 2013-08-14 /pmc/articles/PMC3743899/ /pubmed/23967103 http://dx.doi.org/10.1371/journal.pone.0070775 Text en © 2013 Zanchi et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited. |
spellingShingle | Research Article Zanchi, Cristina Locatelli, Monica Benigni, Ariela Corna, Daniela Tomasoni, Susanna Rottoli, Daniela Gaspari, Flavio Remuzzi, Giuseppe Zoja, Carlamaria Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor |
title | Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor |
title_full | Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor |
title_fullStr | Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor |
title_full_unstemmed | Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor |
title_short | Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor |
title_sort | renal expression of fgf23 in progressive renal disease of diabetes and the effect of ace inhibitor |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3743899/ https://www.ncbi.nlm.nih.gov/pubmed/23967103 http://dx.doi.org/10.1371/journal.pone.0070775 |
work_keys_str_mv | AT zanchicristina renalexpressionoffgf23inprogressiverenaldiseaseofdiabetesandtheeffectofaceinhibitor AT locatellimonica renalexpressionoffgf23inprogressiverenaldiseaseofdiabetesandtheeffectofaceinhibitor AT benigniariela renalexpressionoffgf23inprogressiverenaldiseaseofdiabetesandtheeffectofaceinhibitor AT cornadaniela renalexpressionoffgf23inprogressiverenaldiseaseofdiabetesandtheeffectofaceinhibitor AT tomasonisusanna renalexpressionoffgf23inprogressiverenaldiseaseofdiabetesandtheeffectofaceinhibitor AT rottolidaniela renalexpressionoffgf23inprogressiverenaldiseaseofdiabetesandtheeffectofaceinhibitor AT gaspariflavio renalexpressionoffgf23inprogressiverenaldiseaseofdiabetesandtheeffectofaceinhibitor AT remuzzigiuseppe renalexpressionoffgf23inprogressiverenaldiseaseofdiabetesandtheeffectofaceinhibitor AT zojacarlamaria renalexpressionoffgf23inprogressiverenaldiseaseofdiabetesandtheeffectofaceinhibitor |